Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Shows Direct Link Between H Pylori and Gastric Cancer

October 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

ORLANDO-Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.

ORLANDO—Researchers from Kure, Japan, reported on the first prospective study to show a direct connection between infection with Helicobacter pylori and the onset of gastric cancer. Their work, presented at the Digestive Disease Week meeting, builds upon epidemiologic research done in the early 1990s that strongly suggested such an association.

The study involved 1,166 patients with gastric disease who were tested for H pylori infection. The researchers took pains to ensure the accuracy of all negative readings. Each patient underwent three tests for the presence of H pylori: histology, a rapid urease test, and a serologic test.

“If all three tests were negative, we knew the patient was negative for H pylori,” Naami Uemara, MD, said in an interview. “Each test yields a false negative about 20% of the time. With three tests in agreement, you eliminate false negatives.” Dr. Uemara, chief of gastroenterology at Kure Kyosai Hospital, led the research team.

Of the total group, 246 were negative for H pylori while 920 were positive. Patients who tested positive for H pylori had the following diagnoses: chronic gastritis, (382 patients), active gastric ulcer (186), active duodenal ulcer (180), gastric polyp (172).

All patients underwent endoscopy at least once every 2 years. Therapy to eradicate H pylori was not employed in any of the patients. The follow-up period ranged from 5 to 8.5 years, and averaged 7 years.

Among patients free of H pylori, follow up endoscopy has revealed no cases of gastric cancer. In contrast, at the time of this analysis, the researchers had discovered gastric cancer in 17 of the 920 patients infected with H pylori (P < .05).

Histology revealed that 12 of the gastric cancers were of the intestinal type, and 5 were of the diffuse type. “This led us to conclude that, in humans, H pylori-associated gastritis causes the onset of both types of gastric cancer,” Dr. Uemara commented.

Articles in this issue

Henderson Offers ‘Take-Home Messages’ From Endocrine Studies
Sustained-Release Cytarabine for Lymphomatous Meningitis
Scintimammography Detects Tumors in Dense Breast Tissue
Autologous Vaccine as Adjuvant Therapy for Melanoma
Breast Cancer Screening in Women 40 to 49
Limited Surgery Better in Colon Cancer With Diffuse Liver Mets
Risk Factors for Local Recurrence After Breast-Conserving Therapy
New Brain Imaging Technique Cuts MR Scan Time in Half
NCI Is Testing Thalidomide to Prevent Colorectal Cancer Recurrence
Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art
Geffen Cancer Center Uses Western Medicine, Eastern Philosophy
Fatigue More Severe Than Anticipated in Palliative Medicine
Lower Levels of IGF Binding Protein Seen in High-Risk Black Men
Randomized Trials Needed to Settle Prostate Cancer Controversies
Tamoxifen Plus Goserelin as Adjuvant Therapy
Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content
Advertisement

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

Sabrina Serani
December 8th 2025
Article

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.

Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD

Tim Cortese
December 8th 2025
Article

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

ONCOLOGY Staff
December 8th 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.


5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

Caroline Seymour
December 8th 2025
Article

“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.

Related Content
Advertisement

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

Sabrina Serani
December 8th 2025
Article

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.


Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.

Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD

Tim Cortese
December 8th 2025
Article

Talquetamab plus teclistamab led to an ORR and CR or better rate of 79% and 53%, respectively, in multiple myeloma with true extramedullary disease.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation

ONCOLOGY Staff
December 8th 2025
Article

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.


5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

5-Year+ BRUIN Follow-Up Shows Continued Response With Pirtobrutinib in CLL/SLL

Caroline Seymour
December 8th 2025
Article

“Pirtobrutinib continues to show favorable efficacy and promising overall survival [OS],” said William G. Wierda, MD, PhD.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.